The relationship of cholesterol-lowering drugs with steroid HORMONEs, bile acids, muscle morphology, vitamin D, the immune system and related diseases such as depression and osteoporosis

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-516967-10-00

Acronym

CHORMONE

Enrollment

250

Registered

2024-12-10

Start date

Unknown

Completion date

Unknown

Last updated

2024-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperlipidemia

Brief summary

Changes in sex steroid levels

Interventions

DRUGALIROCUMAB

DRUGROSUVASTATIN

DRUGEVOLOCUMAB

DRUGATORVASTATIN

DRUGINCLISIRAN

DRUGPraluent 150 mg solution for injection in pre-filled pen

DRUGRepatha 140 mg solution for injection in pre-filled syringe

DRUGRosuvastatin 5 mg film-coated tablets

DRUGLeqvio 284 mg solution for injection in pre-filled syringe

DRUGAtorvastatin 10 mg film-coated tablets

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Changes in sex steroid levels	—

Countries

Austria

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026